Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
18F-metaFluorobenzylguanidine · 1 trial · 3 indications
Obtain computer quantification of global and/or regional differences in myocardial sympathetic innervation (based on 18F-mFBG uptake) between subjects who have and have not experienced an appropriate ICD activation within the previous 12 months
| Arm | Type | Description |
|---|---|---|
| Ischemic cardiomyopathy with ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered to intraveously to 10 heart failure patients with ischemic cardiomyopathy and an ICD discharge within the past 12 months |
| Ischemic cardiomyopathy without ICD discharge | ACTIVE_COMPARATOR | 82Rb and 18F-mFBG will be administered intravenously to 10 heart failure patients with ischemic cardiomyopathy and no ICD discharge within the past 12 months |
| Name | Type | Description |
|---|---|---|
| 18F-metaFluorobenzylguanidine | DRUG | PET Radiopharmaceutical to assess myocardial sympathetic innervation |
| Rubidium-82 | DRUG | PET Radiopharmaceutical to assess myocardial perfusion |
Inclusion Criteria: * Stable heart failure from ischemic cardiomyopathy, LVEF \< or = 35%, ICD implantation for at least 12 months Exclusion Criteria: * Unstable coronary artery disease, no ICD implantation
Top 20 of 31 competitors
18F-metaFluorobenzylguanidine is an investigational small molecule being studied for use in heart failure. It is a positron emission tomography (PET) imaging agent designed to assess myocardial sympathetic innervation. The drug is currently in Phase 2 clinical development for this cardiovascular indication.
18F-metaFluorobenzylguanidine targets the sympathetic nervous system in the heart. As a radiolabeled analog of guanethidine, it is taken up by adrenergic nerve terminals, allowing PET imaging to evaluate myocardial sympathetic innervation. This mechanism helps assess nerve function in conditions like heart failure and ischemic cardiomyopathy.
18F-metaFluorobenzylguanidine is being developed by Illumina, Inc., a company traded on NASDAQ under the ticker ILMN. The drug is currently in Phase 2 clinical trials for heart failure and related cardiac conditions.
18F-metaFluorobenzylguanidine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is actively recruiting participants to evaluate the imaging agent in patients with heart failure and ischemic cardiomyopathy.
18F-metaFluorobenzylguanidine is being studied in one active Phase 2 clinical trial, NCT06965621, titled "18F-mFBG Imaging for Myocardial Sympathetic Innervation." This trial is enrolling 20 patients in the United States with heart failure, ischemic cardiomyopathy, or who have implantable cardioverter-defibrillators (ICDs). The study is not yet recruiting participants.
Yes, 18F-metaFluorobenzylguanidine is commonly abbreviated as 18F-mFBG. The clinical trial NCT06965621 uses the abbreviated name in its title, referring to the same investigational PET imaging agent being developed for myocardial sympathetic innervation assessment in heart failure patients.